Edition:
United Kingdom

Neos Therapeutics Inc (NEOS.OQ)

NEOS.OQ on NASDAQ Stock Exchange Global Market

9.95USD
3:54pm GMT
Change (% chg)

$0.10 (+1.02%)
Prev Close
$9.85
Open
$9.85
Day's High
$9.95
Day's Low
$9.85
Volume
43,899
Avg. Vol
160,121
52-wk High
$13.15
52-wk Low
$4.85

Chart for

About

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to... (more)

Overall

Beta: --
Market Cap(Mil.): $255.53
Shares Outstanding(Mil.): 28.08
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Neos Therapeutics reports Q3 loss of $0.58/shr

* Neos Therapeutics reports third quarter 2017 financial results

08 Nov 2017

BRIEF-PDL Biopharma urges Neos Therapeutics to provide update on sale process

* PDL Biopharma's proposal to acquire Neos Therapeutics expires today; PDL urges Neos to provide update on sale process

08 Nov 2017

BRIEF-Neos Therapeutics receives paragraph IV certification from Teva Pharmaceuticals USA

* Neos Therapeutics-co received paragraph iv certification from teva pharmaceuticals usa that teva submitted anda for generic version of cotempla xr-odt​

01 Nov 2017

Neos Therapeutics to consider other offers after PDL snub: sources

U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc , will consider offers from other potential buyers, according to people familiar with the matter.

31 Oct 2017

CORRECTED-Neos Therapeutics to consider other offers after PDL snub -sources

Oct 31 U.S. drugmaker Neos Therapeutics Inc , which this week rejected a fourth takeover offer by PDL Biopharma Inc, will consider offers from other potential buyers, according to people familiar with the matter.

31 Oct 2017

BRIEF-Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma

* Says confirmed it received unsolicited proposal from PDL Biopharma to buy co for $10.25 per share in cash​

26 Oct 2017

BRIEF-PDL BioPharma proposes to acquire Neos Therapeutics for $10.25 per share

* PDL Biopharma proposes to acquire NEOS THERAPEUTICS for $10.25 per share in cash

26 Oct 2017

BRIEF-Neos therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

* Neos Therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation

18 Oct 2017

BRIEF-Neos Therapeutics receives U.S. FDA approval

* Neos Therapeutics receives U.S. FDA approval of Adzenys ER™ (amphetamine) extended-release oral suspension for the treatment of ADHD in patients 6 years and older

15 Sep 2017

BRIEF-Neos Therapeutics announces launch of Cotempla XR-OD extended-release orally disintegrating tablets for treatment of ADHD

* Neos Therapeutics announces launch of Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets for the treatment of ADHD in patients 6 to 17 years old Source text for Eikon: Further company coverage:

05 Sep 2017

Earnings vs. Estimates